Kurzübersicht für Rekombinanter Human IgG1 isotype control (Biotin) (ABIN7488562)
Target
IgG1
Antikörpertyp
Recombinant Antibody
Klonalität
Monoklonal
Konjugat
Biotin
Applikation
Isotype Control (IsoC), ELISA, Western Blotting (WB), Immunohistochemistry (IHC), In vivo Studies (in vivo), Immunofluorescence (IF), In vitro Assay (in vitro), Negative Control (NC)
Güteklasse
MALS verified
Isotyp
IgG1
Wirt
Human
Verwendungszweck
Biotinylated Human IgG1 Kappa Isotype Control (Biotin, mAb, carrier free, MALS verified)
Spezifität
Specifically reacts with DNP (Dinitrophenyl) and DNP conjugated proteins.
Produktmerkmale
Dinitrophenyl (DNP) is a hapten that is not normally expressed in the target tissue. Therefore, anti-DNP antibody has no relevant specificity to a target antigen, and can be used as isotype control antibody to differentiate non-specific background signal from specific antibody signal in various in vitro and in vivo studies. Biotinylated Human IgG1 Kappa Isotype Control (mAb) was purified from HEK293 cell culture. It is the chemically biotin labeled form of Human IgG1 Kappa Isotype Control (mAb) DNP-M2).
This antibody is suitable for use as a non-targeting isotype control in various in vitro and in vivo studies. It can also be used as a negative control in various applications such as ELISA, Western blot, immunofluorescence, immunohistochemistry
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Lagerung
-20 °C
Target
IgG1
Substanzklasse
Antibody
Hintergrund
A hapten is a small molecule that can elicit an immune response only when conjugated with a large carrier such as a protein. Typical haptens include drugs, urushiol, quinone, steroids, etc. Peptides and non-protein antigens usually need conjugating to a carrier protein (such as BSA (bovine serum albumin) or KLH (keyhole limpet hemocyanin) to become good immunogens). Additionally, haptens should be administered with an adjuvant to ensure a high quality immune response. It is important that the hapten design (preserving greatly the chemical structure and spatial conformation of target compound), selection of the appropriate carrier protein and the conjugation method are key conditions for the desired specificity anti-hapten antibodies. We design anti-hapten antibodies based on the HaptenDB information.